Brief: Aclaris Therapeutics Announces Exclusive, Global License Agreement With Biosion
18/11/2024 13:21
Nov 18 (Reuters) - Aclaris Therapeutics Inc ACRS.O :
* ACLARIS THERAPEUTICS ANNOUNCES EXCLUSIVE, GLOBAL LICENSE
AGREEMENT WITH BIOSION, INC., ADDING POTENTIAL BEST-IN-CLASS
BIOLOGICS ASSETS TO PIPELINE
* ACLARIS THERAPEUTICS INC - ENTERED EXCLUSIVE LICENSE
AGREEMENT
WITH BIOSION FOR WORLDWIDE RIGHTS TO BSI-045B & BSI-502
Source text: ID:nGNX61z9C6
Further company coverage: ACRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations